• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Varun Saxena

Varun Saxena

Articles

ARTICLES

Foundation Medicine's cancer diagnostic to receive accelerated reviews from FDA, CMS

Aug. 4, 2016
By Varun Saxena

Foundation Medicine's diagnostic gets speedy reviews from FDA, CMS

Aug. 4, 2016
By Varun Saxena
Foundation Medicine Inc.'s Foundationone pan-cancer comprehensive genomic profiling assay will be reviewed via the FDA's Expedited Access Pathway.
Read More

Pair of guidances outline role of FDA in critical oversight of Precision Medicine Initiative

July 29, 2016
By Varun Saxena
U.S. Center for Device and Radiological Health (CDRH) officials expounded on two crucial guidance documents that describe the FDA’s regulation of next-generation sequencing (NGS), as the agency aims to optimize its oversight of the technology and fulfill its role within President Obama’s Precision Medicine Initiative.
Read More

Pair of guidances outline FDA's role in critical oversight of Precision Medicine initiative

July 28, 2016
By Varun Saxena

HP to partner with Echopixel for virtual reality in the OR

July 25, 2016
By Varun Saxena

Boston Scientific to settle tax dispute with IRS for $275 million, satisfying Wall Street

July 21, 2016
By Varun Saxena
Boston Scientific Corp.'s stock spiked more than 2 percent on news that the company has reached a $275 million settlement with the Internal Revenue Service over transfer pricing issues associated with the company's $27 billion acquisition of Guidant Corp. in 2006. When finalized, the settlement will remove a potential headwind, and demonstrate Boston Scientific's continued recovery from the disastrous takeover of the cardiology implant maker.
Read More

Alere voluntarily pulls Inratio POC blood monitor in response to FDA scrutiny

July 13, 2016
By Varun Saxena
Waltham, Mass.-based Alere Inc. is discontinuing its Inratio and Inratio 2 PT/INR blood monitoring devices after the FDA said a study of the products' software enhancements was inadequate. The company's stock fell more than 3 percent on the news, which will result in charges of between $70 million and $90 million this year.
Read More

Feds request additional information about Abbott's $25 billion merger with St. Jude, putting possible divestments in the cards

July 13, 2016
By Varun Saxena
The U.S. Federal Trade Commission requested more information about the impending $25 billion merger of St. Jude Medical Inc. and Abbott Laboratories, meaning the earliest date at which the deal can close has been extended by 30 days.
Read More

FDA approval of its first bioresorbable stent a win for Abbott Laboratories

July 6, 2016
By Varun Saxena
U.S. heart disease patients will have access to dissolvable, impermanent stents due to the FDA approval of Abbott Laboratories' Asborb bioresorbable stent, which will enable the high-profile device to hit the market after years of clinical trials, and fierce debate over its safety and efficacy.
Read More

Industry fighting could delay CMS reimbursement cuts on DME technology

June 29, 2016
By Varun Saxena
View All Articles by Varun Saxena

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe